康美药业：2025年前三季度归属于上市公司股东的净利润同比增长160.84%

Core Insights - The company reported a revenue of 3,959,603,514.66 yuan for the first three quarters of 2025, representing a year-on-year growth of 2.22% [1] - The net profit attributable to shareholders of the listed company was 13,082,309.31 yuan, showing a significant year-on-year increase of 160.84% [1] Financial Performance - Revenue for the first three quarters of 2025 reached approximately 3.96 billion yuan, indicating a modest growth compared to the previous year [1] - The net profit for the same period was around 13.08 million yuan, reflecting a substantial increase in profitability [1]